This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Lung cancer	Forkhead box O1 (FOXO1); epidermal growth factor receptor (EGFR)	<p>Studies in cell culture and in mice suggest trifluoperazine hydrochloride (TFP) could help restore the sensitivity of lung cancer to EGFR-targeting therapies. The FDA-approved antipsychotic and antiemetic TFP is a known dopamine receptor antagonist and also inhibits FOXO1 nuclear export. In cultured cells treated with the EGFR inhibitor Tarceva erlotinib, cells sensitive to the drug showed greater levels of nuclear FOXO1 and apoptosis than erlotinib-resistant cells. In mice with Tarceva-resistant tumors, TFP plus Tarceva increased levels of nuclear FOXO1 and tumor regression compared with Tarceva alone. Next steps include clinical trials and testing the combination using other EGFR-targeting therapies in other cancers. Tarceva is marketed by Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd. and Roche for non-small cell lung cancer (NSCLC) and pancreatic cancer.</p> <p>SciBX 5(25); doi:10.1038/scibx.2012.652 Published online June 21, 2012</p>	Patent application filed; available for licensing	<p>Sangodkar, J. <i>et al. J. Clin. Invest.</i>; published online June 1, 2012; doi:10.1172/JCI62058 Contact: Goutham Narla, Case Western Reserve University and University Hospitals, Cleveland, Ohio e-mail: goutham.narla@mssm.edu</p>